In the present study, we identified 18 key targets of YXTMD for the treatment of CHD with BSS: EGFR, VEGFA, AKT1, STAT3, TP53, ERBB2, PIK3CA, HSP90AA1, MTOR, SRC, CASP3, MMP9, IL2, NRAS, PTPN11, TNF, PTGS2, and FGF2. This evidence concerns the gene MMP9 and coronary artery disorder.